OCT 09, 2019 9:00 AM PDT

Start at the End: A Strategy for Developing and Delivering Advanced Diagnostic Tests to improve Prostate Cancer Patient Outcomes

Sponsored by: Agilent
C.E. Credits: P.A.C.E. CE Florida CE
Speakers
  • Professor of Proteomics, Founder, CEO and CSO Atturos Ltd. C/O UCD Conway Institute University College Dublin
    Biography
      Steve is Professor of Proteomics at University College Dublin, Ireland. A chemist (Imperial College, London) and PhD biochemist (University of Cambridge) by training.

      Through engagement in a series of collaborations and international consortia, his current biomedical proteomics research is directed to the discovery and development of protein biomarkers. On-going projects are focussed on the mass spectrometry based measurement and evaluation of protein biomarkers in oncology and inflammatory disease to progress them to clinical utility. Steve's team are also investigating the mechanisms of disease progression focussing on prostate cancer and psoriatic arthritis.

      Steve is highly energetic and enthusiastic with an innovative, open and inclusive approach to his work. He has given over 200 invited presentations at international events, published over 80 scientific papers, edited and contributed to several books including editing one of the first books on Proteomics that was translated into Chinese and Japanese. Steve has held roles as a committee member in the British Society for Proteome Research (currently vice-President, and the European Proteomics Association. He is the lead organiser of the forthcoming annual world congress of the Human Proteome Organisation (HUPO) that will be held in the national Convention Centre in Dublin from 17-21st September 2017 (www.hupo2017.ie).

      Recently, Steve founded the UCD spinout company 'Atturos' (Dec 2016) to support the delivery of OCProDx to clinical use. OCProDx is a prostate cancer blood-based biomarker test that has the capability to distinguish patients with organ-confined and non-organ confined disease. The test will help inform men diagnosed with prostate cancer whether they should go on or stay on 'active surveillance' The Atturos team has the expertise and experience to deliver this and other multiplexed protein biomarker tests to market.

    Abstract:

    Although about one in every seven men in the developed world will be diagnosed with prostate cancer in their lifetime, the mortality rate remains low with a 99% five-year survival rate for low to intermediate grade disease. Following diagnosis, surgery (radical prostatectomy), radiation therapy, hormonal therapy and chemotherapy either singly or in combinations are options for initial treatment. However, active surveillance - where disease progression is carefully monitored - may be a more appropriate option for less advanced and low grade disease.

    At present a diagnosis of prostate cancer is initially and most commonly made on the basis of three investigations: the prostate specific antigen (PSA) test, digital rectal examination (DRE) and biopsy-based grading of the tumour by histopathology. It is accepted that these tests do not provide adequate information to support the decision of whether to pursue immediate treatment or active surveillance. Hence, there is a significant unmet need for specific and sensitive biomarkers to guide the decision between treatment and active surveillance, as well as for regular monitoring of disease progression in men on active surveillance.  

    Despite a few decades of proteomics research and the apparent discovery of multiple protein biomarkers to support the diagnosis and treatment decisions, the number of protein biomarkers that have been developed to the stage of being used routinely is disappointingly low.  So, it's clear that whilst there’s a huge need to develop new protein biomarkers as yet biomarker development and delivery is proving very challenging.  Why is this?

    This presentation will demonstrate how SRM/MRM on triple quadrupole mass spectrometers affords huge potential as a platform for the development of specific and sensitive 'biomarker signatures' comprising multiple proteins.   Strategies for the delivery and implementation of multiplexed protein biomarkers to support improved clinical decision making following prostate cancer diagnosis will be described.

    Learning Objectives:

    1. Appreciate the challenges faced in the management of prostate cancer
    2. Recognise the need for authentic protein biomaker discovery and strategies to acheive it
    3. Undertand how MRM can be used for the development of analytically validated protein biomarker signatures.
    4. Appreciate the challenges associated with the delivery of biomarker signatures for routine use and improved prostate cancer patient outcomes.

     

     

    For Research Use Only. Not for use in diagnostic procedures.

     


    Show Resources
    You May Also Like
    SEP 05, 2019 4:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 4:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    NOV 18, 2019 7:00 AM PST
    C.E. CREDITS
    NOV 18, 2019 7:00 AM PST
    DATE: November 18, 2019TIME: 7:00am PST, 11:00am EST, 4:00pm CEWT How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop th...
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    MAR 03, 2020 9:00 AM JST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    MAR 03, 2020 9:00 AM JST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: March 3, 2020 TIME: 9:00am JST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid differentiation of HSPCs at the e...
    FEB 25, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 25, 2020 9:00 AM PST
    Learn about how to generate a small scale CAR-T workflow using ThermoFisher products See detailed characterization tools that can be utilized and applied in a CAR-T workflow...
    DEC 10, 2019 9:00 AM PST
    C.E. CREDITS
    DEC 10, 2019 9:00 AM PST
    DATE: December 10, 2019TIME: 9:00am PST, 12:00pm EST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid dif...
    Loading Comments...
    Show Resources
    Attendees